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Abstract To identify proteins potentially involved in osteoclast
di¡erentiation, we conducted a proteomics-based analysis using
the osteoclastogenesis model cell line RAW264.7. Total proteins
from undi¡erentiated cells, committed pre-osteoclasts, and dif-
ferentiated osteoclasts were resolved by two-dimensional gel
electrophoresis. Protein spots showing di¡erential expression
levels were processed for peptide mass ¢ngerprinting. Among
them, we identi¢ed the metallocarboxypeptidase CPX-1, which
was prominently increased in pre-osteoclasts and then decreased
in mature osteoclasts. Results of reverse transcription polymer-
ase chain reaction, Western blot, and confocal microscopy were
in agreement with the proteomics data. Notably, the forced
overexpression of CPX-1 led to the inhibition of osteoclast for-
mation, but not pre-osteoclast generation. Therefore, the tran-
sient up-regulation pattern of CPX-1 expression may be impor-
tant for the successful progression from pre-osteoclasts to
mature osteoclasts.
) 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Bone homeostasis is maintained through bone remodeling,
which results from the coordinated action of bone resorption
by osteoclasts and new bone formation by osteoblasts. Osteo-
clasts di¡erentiate from hematopoietic myeloid precursors of
the monocyte/macrophage lineage, and play pivotal roles in
bone morphogenesis, remodeling, and resorption [1,2]. It is
now widely accepted that the interaction between receptor
activator of NF-UB ligand (RANKL), expressed by stromal
cells/osteoblasts, and its receptor RANK, expressed on osteo-
clast precursors, is essential for osteoclastogenesis [3]. RANK,
a member of tumor necrosis factor (TNF) family proteins,
transduces biochemical signals by recruiting TNF receptor-
associated factor proteins causing the activation of NF-UB
and mitogen-activated protein kinases (MAPK) [4^8]. How-
ever, only a few target proteins of RANKL stimulation have
been elucidated.
Members of the carboxypeptidase gene family have been
implicated in diverse functions including neuroendocrine pep-
tide processing as well as food digestion [9]. CPX-1 was iden-
ti¢ed as a novel member of a distinct subgroup of the metal-
locarboxypeptidase gene family [10]. Despite homology with
carboxypeptidases, CPX-1 lacks several residues important for
the catalytic activity and did not show enzyme activity when
expressed in either the baculovirus system or a mouse cell line
[10]. In addition, CPX-1 contains an N-terminal region of 160
amino acids with sequence similarity to the discoidin domain
as do two other inactive metallocarboxypeptidases, CPX-2
and AEBP1/ACLP [10]. The discoidin domain has been found
in mammalian milk proteins, blood coagulation factors, and
receptor tyrosine kinases and has been suggested to function
in cell aggregation, adhesion, and cell^cell recognition [11]. In
this context, mice de¢cient in AEBP1/ACLP displayed defects
in abdominal wall development and dermal wound healing
[11]. In situ hybridization of CPX-1 mRNA revealed an abun-
dant expression in developing skeletal structures and a role in
development was proposed for CPX-1 [10]. However, studies
on CPX-1 have been very limited and understanding of the
exact function of CPX-1 needs further investigations.
In this study, we performed a proteomics-based analysis to
¢nd proteins potentially involved in RANKL-induced osteo-
clast di¡erentiation and identi¢ed CPX-1 as a protein whose
expression level is regulated during osteoclastogenesis.
2. Materials and methods
2.1. Materials
Recombinant soluble human RANKL was purchased from Pepro-
tech EC (London, UK) and murine macrophage/colony-stimulating
factor from RpD Systems (Minneapolis, MN, USA). Polyclonal anti-
bodies against CPX-1 were generated by immunizing rabbits with a
murine CPX-1 peptide (STKANETSERHVRLRC).
2.2. In vitro generation of osteoclasts and determination of osteoclast
phenotype
In vitro osteoclast generation was conducted as previously de-
scribed with a slight modi¢cation [12]. RAW264.7 murine mono-
cyte/macrophage cells were incubated in K-MEM containing 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U of penicillin and 100
Wg/ml streptomycin in the presence of 100 ng/ml RANKL. Cell phe-
notype was determined by staining for tartrate-resistant acid phospha-
tase (TRAP) activity (Acid-Phosphatase Kit; Sigma-Aldrich). After
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2 days of culture in the presence of RANKL, more than 90% of cells
were TRAP-positive mononuclear and cells at this stage were consid-
ered pre-osteoclasts. Mature TRAP-positive multinucleated osteo-
clasts were obtained after culturing for 3 days.
2.3. Two-dimensional gel electrophoresis (2-DE) and peptide mass
¢ngerprinting
2-DE was carried out in a horizontal electrophoresis system, Multi-
phor II system (Amersham Pharmacia, Piscataway, NJ, USA). The
¢rst-dimensional isoelectric focusing was conducted for 72 kVh using
Immobiline dry strips (24 cm long, non-linear gradient between pH 4
and 7, Amersham Pharmacia). After the ¢rst dimension separation,
the IPG gel was equilibrated twice in equilibration bu¡er consisting of
50 mM Tris^HCl (pH 6.8), 6 M urea, 2% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.002% (w/v) bromophenol blue.
1% (w/v) dithiothreitol was included in the equilibration bu¡er for
the ¢rst equilibration step and 2.5% (w/v) iodoacetamide for the sec-
ond equilibration step. The equilibrated IPG gel was subjected to the
second-dimensional SDS^polyacrylamide gel electrophoresis (PAGE).
Proteins on the gel were visualized by silver staining. Protein spots
were cut, subjected to reduced S-carboxymethylation, dehydrated in
100% acetonitrile, dried in a Speed-Vac, and soaked in digestion bu¡-
er containing trypsin. After overnight digestion, peptide fragments in
the supernatant were desalted by Zip tips C18 (Millipore, Bedford,
MA, USA). Peptide mass maps were obtained using a matrix-assisted
laser desorption/ionization-time of £ight (MALDI-TOF) mass spec-
trometer (Voyager DE-STR, Applied Biosystems, Foster City, CA,
USA) at an instrument resolution in excess of 6000 over the m/z range
700^3500 Da. Protein identi¢cation was carried out using the MS-¢t
search engine in ProteinProspector (University of California San
Francisco) by sending a query of the subtracted peptide mass data.
2.4. Reverse transcription polymerase chain reaction (RT-PCR)
analysis
Total RNA was extracted from cells using Trizol (Invitrogen, Carls-
bad, CA, USA), and then reverse-transcribed for cDNA synthesis
according to the manufacturer’s instructions (Invitrogen). PCR was
carried out in a Perkin Elmer thermal cycler for 35 cycles consisting of
30 s denaturation at 94‡C, 1 min annealing at 56‡C, and 1 min
extension at 72‡C. The sequence of the sense primer was 5P-
ATAGGGCCATGCAGGATAC-3P) and that of the antisense primer
was 5P-TGGGAGTCTTGGTGAGTAG-3P. PCR products were visu-
alized by subjecting to electrophoresis in a 2% agarose gel and stain-
ing with ethidium bromide.
2.5. Western blot analysis
Western blotting analyses were performed as previously described
[13]. Cells were lysed in lysis bu¡er (10 mM Tris, 50 mM NaCl, 5 mM
EDTA, 50 mM NaF, 30 mM sodium pyrophosphate, 100 mM sodium
orthovanadate, 200 mM phenylmethylsulfonyl £uoride, 10 Wg/ml leu-
peptin, and 5 Wg/ml aprotinin, 1% NP-40). The protein concentrations
of the cell lysates were determined by Bradford assay and then equal
amounts of proteins were loaded into 8% SDS^PAGE. Gels were
blotted onto nitrocellulose membrane and incubated with polyclonal
anti-mCPX-1 antibody. The immunoreactive proteins were detected
with ECL reagents after incubation with anti-rabbit IgG-horseradish
peroxidase.
2.6. Confocal microscopy
Cells were ¢xed with 3.7% formaldehyde/phosphate-bu¡ered saline
(PBS) for 5 min and permeabilized in 0.5% saponin for 20 min. After
blocking with 2% bovine serum albumin/PBS, cells were stained with
polyclonal anti-mCPX-1 and Cy3-conjugated anti-rabbit IgG antibod-
ies. Actin stress ¢bers were stained with £uorescein isothiocyanate
(FITC)-labeled phalloidin (Sigma-Aldrich) to show cell entity in the
photographed ¢eld. Fluorescent images were collected using a confo-
cal microscope (Leica).
2.7. CPX-1 expression plasmid construction and RAW264.7 cell
transfection
The pVL1393 plasmid harboring the full-length cDNA of mouse
CPX-1 was generously provided by Dr. L.D. Fricker (Albert Einstein
College of Medicine, Bronx, NY, USA). The CPX-1 cDNA was sub-
cloned into pcDNA3.1(+) using BamHI and EcoRI sites. RAW264.7
cells were transiently transfected with pcDNA3.1(+)-CPX-1 plasmid.
Cells (1U105/well) were seeded onto six-well plates 24 h prior to
transfection. The plasmid DNA was incubated for 20 min at room
temperature in serum-free medium containing LipofectAMINE 2000
reagent (Invitrogen). The DNA^LipofectAMINE complexes were
added dropwise to the cells. After 3^5 h incubation at 37‡C, the cells
were washed and incubated in fresh medium containing 10% FBS for
24 h. Cells were induced to di¡erentiate to osteoclasts by treating with
RANKL.
2.8. Statistical analysis
Statistical di¡erences were analyzed by Student’s t-test. All experi-
ments were repeated three or four times, and results from a represen-
tative experiment are shown.
3. Results
To identify proteins di¡erentially regulated during
RANKL-induced osteoclastogenesis, we employed the model
cell line RAW264.7. This type of cells has been well charac-
terized to di¡erentiate into functional osteoclasts when cul-
tured in the presence of RANKL [14]. These cells became
positive for TRAP, a frequently used marker of committed
and di¡erentiated osteoclasts, 2 days after incubation with
RANKL (Fig. 1A, panel b). Most of the cells at this stage
were mononuclear with a few cells in the process of fusion.
TRAP-positive multinuclear cells were generated after cultur-
ing with RANKL for 3 days (Fig. 1A, panel c). For proteome
analyses, cells at each stage shown in Fig. 1A were lysed and
cellular proteins were subjected to 2-DE and MALDI-TOF
analysis as described in Section 2. Several groups of protein
spots were down- or up-regulated by RANKL treatment.
Among the proteins identi¢ed by MALDI-TOF, we further
analyzed a protein spot of which the best matched PMF was
the metallocarboxypeptidase CPX-1 (GenBank accession
number Q9Z100). On 2-DE gels this protein showed an ap-
proximate molecular mass of 80 kDa and pI of 6.5. The ex-
pression levels of this protein increased as cells changed to
pre-osteoclasts and then decreased as cells further di¡erenti-
ated to multinuclear osteoclasts (Fig. 1B,C). Eleven peptides
matched with less than 50 delta ppm covering 15% of the total
sequence over eight regions (Fig. 1D). The theoretical molec-
ular weight (80.9 kDa) and pI (6.41) values were closely
matched with those estimated from 2-DE.
To evaluate the validity of the proteomics result, we ¢rst
examined the expression levels of CPX-1 mRNA and protein
during osteoclastogenesis. When determined by RT-PCR,
CPX-1 mRNA expression was found to be elevated at the
pre-osteoclast stage after culturing for 2 days with RANKL
and then diminished in mature osteoclasts at day 3 of culture
(Fig. 2A). This result indicates that changes in CPX-1 mRNA
levels occur during osteoclast di¡erentiation, which could be
due to either transcriptional or posttranscriptional events af-
fected by RANKL stimulation. To assess the protein levels,
we raised rabbit antiserum toward mouse CPX-1 using a syn-
thetic peptide. This antibody successfully recognized mouse
CPX-1 expressed in human embryonic kidney cell line 293
by transient transfection (data not shown). Western blotting
analyses with this antibody of cell lysates from the di¡erent
stages of osteoclastogenesis showed that CPX-1 protein was
also increased in pre-osteoclasts and declined in multi-
nucleated osteoclasts (Fig. 2B). This pattern of CPX-1 protein
expression was also observed during di¡erentiation of osteo-
clasts from bone marrow cells (data not shown). Similarly,
immunostaining of permeabilized cells with the anti-CPX-1
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antibody revealed a clear staining in pre-osteoclasts (Fig. 3,
panel b) whereas di¡erentiated osteoclasts had very low stain-
ing (Fig. 3, panel d). Overall these results support the proteo-
mic identi¢cation of CPX-1 as a protein transiently up-regu-
lated during osteoclastogenesis.
We next sought to examine the biological signi¢cance of
CPX-1 in relation to osteoclast di¡erentiation. The expression
pattern of CPX-1 suggests that timely changes in CPX-1 levels
may be important for osteoclastogenesis. With this assump-
tion, we thought that a disturbance in the regulated expres-
sion of CPX-1 might interfere with the successful di¡erentia-
tion of osteoclasts. To test our hypothesis, we conducted a
transient transfection of RAW264.7 cells with a CPX-1 ex-
pression plasmid and evaluated the formation of pre-osteo-
clasts as well as multinucleated osteoclasts in response to
RANKL stimulation. The overexpression of CPX-1 was con-
¢rmed by Western blotting to be dependent on the amount of
plasmid used (Fig. 4A). The CPX-1 transfection had little
Fig. 2. The expression patterns of CPX-1 mRNA and protein dur-
ing osteoclastogenesis. A: RAW264.7 cells were cultured in the pres-
ence or absence of RANKL (100 ng/ml) for 2 or 3 days. Total
RNA was prepared and the CPX-1 mRNA levels were assessed by
RT-PCR. B: Total lysates were obtained from cells cultured as in
A. The lysate proteins were resolved by SDS^PAGE. Protein levels
of CPX-1 were determined by Western blotting with a CPX-1 poly-
clonal antibody. The L-actin blot is shown as a loading control.
Fig. 3. Immuno£uorescence microscopy for CPX-1 expression in
osteoclasts. RAW264.7 cells were incubated for 2 (a and b) or 3 (c
and d) days in the presence of 100 ng/ml RANKL. Cells were ¢xed
and permeabilized prior to staining with rabbit antiserum to CPX-1.
Subsequently cells were incubated with Cy3-conjugated anti-rabbit
IgG and FITC-labeled phalloidin. Fluorescence images of cells were
captured under a confocal microscope. CPX-1 staining patterns are
shown in panels b and d. The actin cytoskeleton images of cells in
the same ¢elds are shown in panels a and c. Bar, 100 Wm.
Fig. 1. Identi¢cation of CPX-1 by proteomics analysis. A:
RAW264.7 cells were seeded at 1U105/well in six-well plates and in-
cubated for 2 days (b) or 3 days (c) with 100 ng/ml RANKL. These
cells and undi¡erentiated RAW264.7 cells (a) were stained for
TRAP as described in Section 2. Bar, 200 Wm. B: Cells at each
stage were lysed and cellular proteins were resolved by 2-DE. The
gels were silver-stained and scanned. Protein spots showing di¡eren-
tial expression levels were subjected to trypsin digestion and mass
spectrometry was performed using MALDI-TOF. The protein spots
indicated by arrows were identi¢ed as CPX-1. C: The density of
CPX-1 spots was measured from three gels. Data are expressed as
meansUS.D. **P6 0.02 vs. undi¡erentiated cells. D: The amino
acid sequences of peptides matching the database in the PMF analy-
sis are shown.
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e¡ect on the generation of pre-osteoclasts except the highest
amount of plasmid, which showed a moderate inhibition (Fig.
4B). However, the generation of multinucleated osteoclasts
was signi¢cantly a¡ected at all doses of transfected DNA.
The number of di¡erentiated osteoclasts decreased by
22.6%, 35.5%, and 82.3% at 1, 2, and 3 Wg DNA, respectively
(Fig. 4C). These ¢ndings imply that the controlled expression
of CPX-1 is important for osteoclast di¡erentiation and the
down-regulation of CPX-1 after pre-osteoclast stage is neces-
sary for successful progression of the multinucleation step
during osteoclastogenesis.
4. Discussion
Using a proteomic analysis, we found that the expression of
CPX-1 is regulated during osteoclastogenesis. The protein lev-
el of CPX-1 is very low in undi¡erentiated progenitor cells,
while it increases as cells change to committed pre-osteoclasts.
The CPX-1 level then decreases as cells further di¡erentiate to
multinuclear mature osteoclasts. This expression timing im-
plies that the CPX-1 gene may have a role speci¢cally at the
pre-osteoclast stage.
It was shown that CPX-1 mRNA was abundantly expressed
in primordial cartilage and skeletal structures of embryonic
and fetal mouse tissues [10]. In thorax, CPX-1 mRNA was
detected in multiple developing skeletal structures including
chondrocytes and perichondrial cells of the ribs, vertebrae,
and long-bone primordia [10]. This expression pattern led to
the suggestion that CPX-1 may have a function in skeletal
development. CPX-1 may regulate osteoclastogenesis during
skeletal development. However, studies on CPX-1 have been
scarce and more investigations are needed to obtain support-
ing evidence.
The structural characteristics of CPX-1 include a carboxy-
peptidase homology domain and a discoidin-like domain [10].
Despite the presence of homology to other carboxypeptidases,
CPX-1 failed to show the catalytic activity [10]. These features
are also found in two other metallocarboxypeptidase family
proteins, CPX-2 and AEBP1/ACLP [15]. The lack of enzy-
matic function has drawn attention to the discoidin-like do-
main in exploring roles of this subgroup of the carboxypepti-
dase family.
The slime mold protein discoidin I is secreted and functions
in cell aggregation in Dictyostelium. AEBP1/ACLP, an inac-
tive carboxypeptidase group protein with discoidin-like do-
main, is secreted into the extracellular matrix (ECM) of col-
lagen-rich tissues including the vasculature, dermis, and the
developing skeleton [11]. In adipogenesis of 3T3-L1 cells, a
concurrent decrease in AEBP1/ACLP expression and ECM
stability was observed during the early phase of di¡erentiation
[15]. The discoidin domain of discoidin domain receptor pro-
teins binds various types of collagen [16]. These ¢ndings have
led to the postulation that extracellular discoidin domain-con-
taining proteins bind collagen via the discoidin domain and
facilitate ECM stabilization. One possibility for the role of
CPX-1 in osteoclastogenesis is the regulation of ECM stability
through its discoidin domain. It is likely that ECM compo-
nents are destabilized in order for cells to undergo morpho-
logical changes for fusion. CPX-1, which may facilitate ECM
stabilization, then needs to be down-regulated for the progres-
sion of multinucleation during osteoclastogenesis. Interference
with this timely down-regulation of CPX-1 by ectopic over-
expression might cause a disturbance in the formation of mul-
tinuclear osteoclasts (Fig. 4). In line with this notion, we ob-
served an augmenting e¡ect of the CPX-1 antibody on
multinucleation, which might have been exerted through neu-
tralizing e¡ects of the antibody (data not shown).
Intracellular functions of the discoidin domain have also
been reported. AEBP1/ACLP, whose expression decreases
during adipocyte di¡erentiation, has a transcription repressor
activity [17]. The transcription repression by AEBP1/ACLP is
greatly attenuated by deletion of its discoidin domain [18].
However, whether the deletion caused conformational
changes and/or loss of recruitment of an interacting protein
that is directly involved in repression or whether the discoidin
domain itself has a repressor activity needs to be clari¢ed. In
either case, the possibility can be considered that CPX-1 has a
transcription repressor activity and its discoidin domain func-
tions in an analogous way to that of AEBP1/ACLP. Indepen-
dent of the transcription repressor function, AEBP1/ACLP
can regulate MAPK activation during adipogenesis [18]. The
MAPK modulation appears to be mediated by the discoidin
domain through binding to MAPK and protection from a
MAPK phosphatase [18]. Whether the discoidin domain of
CPX-1 has a similar function during osteoclastogenesis is an
intriguing question to be addressed.
In summary, we report a regulated expression of the metal-
locarboxypeptidase family member CPX-1 during osteoclast
di¡erentiation driven by RANKL. Furthermore, our results
suggest that CPX-1 expression needs to be controlled for suc-
cessful progression of multinucleation during osteoclastogen-
esis. Our ¢ndings raise a potential importance of CPX-1 for
the di¡erentiation of osteoclasts and warrant more studies to
Fig. 4. Inhibition of osteoclast formation by CPX-1 overexpression.
A: RAW264.7 cells were transfected with indicated amounts of mu-
rine CPX-1 plasmid or 3 Wg of the vector DNA. Twenty-four hours
after transfection, CPX-1 levels were examined by Western blotting.
B: Transfected cells were incubated with 100 ng/ml of RANKL for
2 days and stained for TRAP. The percentage of TRAP-positive
pre-osteoclasts was determined. *P6 0.05 vs. mock-transfected cells.
C: After 3 days of RANKL treatment, osteoclast formation was an-
alyzed by TRAP assay. The numbers of TRAP-positive multinuclear
cells are presented. Data are expressed as meansUS.D. *P6 0.05;
**P6 0.02 vs. mock-transfected cells.
FEBS 28291 8-4-04 Cyaan Magenta Geel Zwart
E.-J. Chang et al./FEBS Letters 564 (2004) 166^170 169
understand the molecular mechanism by which CPX-1 func-
tions in osteoclasts.
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